Radio and PodcastLive Radio & PodcastsScience & Medicine
147 - Crizotinib breakthrough therapy designation; certolizumab for moderate-to-severe plaque psoriasis; Zeto wireless EEG headset; larotrectinib in solid tumors; Raviten for intradialytic hypotension
147 - Crizotinib breakthrough therapy designation; certolizumab for moderate-to-severe plaque psoriasis; Zeto wireless EEG headset; larotrectinib in solid tumors; Raviten for intradialytic hypotension is an episode from...
About This Episode
147 - Crizotinib breakthrough therapy designation; certolizumab for moderate-to-severe plaque psoriasis; Zeto wireless EEG headset; larotrectinib in solid tumors; Raviten for intradialytic hypotension is an episode from New FDA Approvals. T...
Podcast
This episode belongs to New FDA Approvals.
Listen Online
Use the player on this page to stream the episode online.
Episode Details
Published May 30, 2018, 13:48 long, audio available.
Related Episodes
Continue listening to more episodes from New FDA Approvals.
Questions About This Episode
What is 147 - Crizotinib breakthrough therapy designation; certolizumab for moderate-to-severe plaque psoriasis; Zeto wireless EEG headset; larotrectinib in solid tumors; Raviten for intradialytic hypotension about?
147 - Crizotinib breakthrough therapy designation; certolizumab for moderate-to-severe plaque psoriasis; Zeto wireless EEG headset; larotrectinib in solid tumors; Raviten for intradialytic hypotension is a podcast episode from New FDA Approvals. You can listen online and use the related episode section to continue with more content from the same show.
Where can I listen to 147 - Crizotinib breakthrough therapy designation; certolizumab for moderate-to-severe plaque psoriasis; Zeto wireless EEG headset; larotrectinib in solid tumors; Raviten for intradialytic hypotension?
You can listen to 147 - Crizotinib breakthrough therapy designation; certolizumab for moderate-to-severe plaque psoriasis; Zeto wireless EEG headset; larotrectinib in solid tumors; Raviten for intradialytic hypotension online on Radio and Podcast. Open the player on this page to stream the available audio.
Which podcast is 147 - Crizotinib breakthrough therapy designation; certolizumab for moderate-to-severe plaque psoriasis; Zeto wireless EEG headset; larotrectinib in solid tumors; Raviten for intradialytic hypotension from?
147 - Crizotinib breakthrough therapy designation; certolizumab for moderate-to-severe plaque psoriasis; Zeto wireless EEG headset; larotrectinib in solid tumors; Raviten for intradialytic hypotension is an episode from New FDA Approvals.
How long is this episode?
This episode is 13:48 long.
When was this episode published?
This episode was published on May 30, 2018.
Can I save 147 - Crizotinib breakthrough therapy designation; certolizumab for moderate-to-severe plaque psoriasis; Zeto wireless EEG headset; larotrectinib in solid tumors; Raviten for intradialytic hypotension for later?
Yes. Use the heart button on the episode page to add it to your favorite episodes list.
Are there related episodes from New FDA Approvals?
Yes. This page shows related episodes from New FDA Approvals when more episodes are available from the podcast feed.
Quick Answers About This Episode
Where can I listen to 147 - Crizotinib breakthrough therapy designation; certolizumab for moderate-to-severe plaque psoriasis; Zeto wireless EEG headset; larotrectinib in solid tumors; Raviten for intradialytic hypotension?
You can listen to 147 - Crizotinib breakthrough therapy designation; certolizumab for moderate-to-severe plaque psoriasis; Zeto wireless EEG headset; larotrectinib in solid tumors; Raviten for intradialytic hypotension on this page when the episode audio is available from the podcast feed.
Which podcast is this episode from?
147 - Crizotinib breakthrough therapy designation; certolizumab for moderate-to-severe plaque psoriasis; Zeto wireless EEG headset; larotrectinib in solid tumors; Raviten for intradialytic hypotension is from New FDA Approvals.
What are the episode details?
Published May 30, 2018 and 13:48 long